Leber Hereditary Optic Neuropathy Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Leber Hereditary Optic Neuropathy remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 23 matched trial records and 36 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600126672 | Intervention not normalized | Phase 4; Recruiting | Peking Union Medical College Hospital; Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences | China | visual acuity | 2029-12-31 |
| ACTRN12626000358347 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Sydney Union | Australia, New Zealand | Primary endpoint not listed | Timing not listed |
| NCT07406854 | Esonadogene Imvoparvovec | Phase 3; Active, not recruiting | 纽福斯生物科技有限公司 | China | Efficacy of NR082 in study eye (52 weeks) | 2026-05-30 |
| NCT07303296 | Lenadogene nolparvovec | Phase 2; Recruiting | Gensight Biologics SA | France | The primary endpoint will be the BCVA change from baseline to 1.5 years post-treatment in the study eyes. (from baseline to 1.5 years post-treatment) | 2028-05-15 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year (Phase 3): the indexed record reports Change From Baseline of the Best Corrected Visual Acuity (BCVA) Reported With Log of the Minimal Angle of Resolution (LogMAR) at 1.5 Years Post-treatment, in the Second Affected/Not-yet Affected Eyes(Least Squares Mean) = -0.04 logMAR (Standard Error, 0.071); Change From Baseline of the Best Corrected Visual Acuity (BCVA) Reported With Log of the Minimal Angle of Resolution (LogMAR) at 1.5 Years Post-treatment, in the Second Affected/Not-yet Affected Eyes(Least Squares Mean): LS Mean Difference (Final Values) = -0.05(95% CI, -0.25 to 0.15), P-Value = 0.608; Change From Baseline of the Best Corrected Visual Acuity (BCVA) Reported With Log of the Minimal Angle of Resolution (LogMAR) at 1.5 Years Post-treatment, in the Second Affected/Not-yet Affected Eyes(Least Squares Mean): LS Mean Difference (Final Values) = -0.05(95% CI, -0.25 to 0.15), P-Value = 0.608.
- Long-Term Outcomes of Bilateral Injection of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy (Phase 3): the indexed record reports BCVA(from nadir to 4 years) = -0.38 LogMAR ( 0.41); BCVA(from nadir to 4 years) = -0.4 LogMAR ( 0.32).
- The Latest Data from Lenadogene Nolparvovec Gene Therapy Trials for Leber Hereditary Optic Neuropathy (S14.001) (Not Applicable): the indexed record reports BCVA = +20 letters; BCVA = +22 letters; BCVA = +20 letters.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Esonadogene Imvoparvovec (Phase 3; MT-ND4), Lenadogene nolparvovec (Phase 3; MT-ND4). Company & Deal Intelligence records identify sponsor context for Peking Union Medical College Hospital, Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences, University of Sydney Union, 纽福斯生物科技有限公司, Gensight Biologics SA (SIGHT). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Endpoints that capture daily function and treatment burden alongside biological change.
- Long-duration comparisons against current procedural or pharmacologic standards.
- Evidence across diverse ages, disease stages and reproductive contexts.
- Delivery approaches that improve persistence without sacrificing safety.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Leber Hereditary Optic Neuropathy has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
